202 related articles for article (PubMed ID: 24644264)
1. Tumor cell-expressed SerpinB2 is present on microparticles and inhibits metastasis.
Schroder WA; Major LD; Le TT; Gardner J; Sweet MJ; Janciauskiene S; Suhrbier A
Cancer Med; 2014 Jun; 3(3):500-13. PubMed ID: 24644264
[TBL] [Abstract][Full Text] [Related]
2. Deficiency of plasminogen activator inhibitor-2 results in accelerated tumor growth.
Westrick RJ; Røjkjaer LP; Yang AY; Roh MH; Siebert AE; Ginsburg D
J Thromb Haemost; 2020 Nov; 18(11):2968-2975. PubMed ID: 32780555
[TBL] [Abstract][Full Text] [Related]
3. SerpinB2 inhibits migration and promotes a resolution phase signature in large peritoneal macrophages.
Schroder WA; Hirata TD; Le TT; Gardner J; Boyle GM; Ellis J; Nakayama E; Pathirana D; Nakaya HI; Suhrbier A
Sci Rep; 2019 Aug; 9(1):12421. PubMed ID: 31455834
[TBL] [Abstract][Full Text] [Related]
4. Down-regulation of SerpinB2 is associated with gefitinib resistance in non-small cell lung cancer and enhances invadopodia-like structure protrusions.
Bae SY; Park HJ; Hong JY; Lee HJ; Lee SK
Sci Rep; 2016 Aug; 6():32258. PubMed ID: 27558531
[TBL] [Abstract][Full Text] [Related]
5. A physiological function of inflammation-associated SerpinB2 is regulation of adaptive immunity.
Schroder WA; Le TT; Major L; Street S; Gardner J; Lambley E; Markey K; MacDonald KP; Fish RJ; Thomas R; Suhrbier A
J Immunol; 2010 Mar; 184(5):2663-70. PubMed ID: 20130210
[TBL] [Abstract][Full Text] [Related]
6. Dependence on endocytic receptor binding via a minimal binding motif underlies the differential prognostic profiles of SerpinE1 and SerpinB2 in cancer.
Cochran BJ; Croucher DR; Lobov S; Saunders DN; Ranson M
J Biol Chem; 2011 Jul; 286(27):24467-75. PubMed ID: 21606492
[TBL] [Abstract][Full Text] [Related]
7. The serine protease inhibitor serpinB2 binds and stabilizes p21 in senescent cells.
Hsieh HH; Chen YC; Jhan JR; Lin JJ
J Cell Sci; 2017 Oct; 130(19):3272-3281. PubMed ID: 28794016
[TBL] [Abstract][Full Text] [Related]
8. The role of SerpinB2 in immunity.
Schroder WA; Major L; Suhrbier A
Crit Rev Immunol; 2011; 31(1):15-30. PubMed ID: 21395508
[TBL] [Abstract][Full Text] [Related]
9. Differential mRNA expression of urokinase-type plasminogen activator, plasminogen activator receptor and plasminogen activator inhibitor type-2 in normal human endometria and endometrial carcinomas.
Foca C; Moses EK; Quinn MA; Rice GE
Gynecol Oncol; 2000 Nov; 79(2):244-50. PubMed ID: 11063652
[TBL] [Abstract][Full Text] [Related]
10. The urokinase plasminogen activation system in gastroesophageal cancer: A systematic review and meta-analysis.
Brungs D; Chen J; Aghmesheh M; Vine KL; Becker TM; Carolan MG; Ranson M
Oncotarget; 2017 Apr; 8(14):23099-23109. PubMed ID: 28416743
[TBL] [Abstract][Full Text] [Related]
11. Is there a role for urokinase-type plasminogen activator inhibitors as maintenance therapy in patients with ovarian cancer?
van Dam PA; Coelho A; Rolfo C
Eur J Surg Oncol; 2017 Feb; 43(2):252-257. PubMed ID: 27345498
[TBL] [Abstract][Full Text] [Related]
12. microRNA-200c/141 upregulates SerpinB2 to promote breast cancer cell metastasis and reduce patient survival.
Jin T; Suk Kim H; Ki Choi S; Hye Hwang E; Woo J; Suk Ryu H; Kim K; Moon A; Kyung Moon W
Oncotarget; 2017 May; 8(20):32769-32782. PubMed ID: 28427146
[TBL] [Abstract][Full Text] [Related]
13. Lack of plasminogen activator inhibitor-1 effect in a transgenic mouse model of metastatic melanoma.
Eitzman DT; Krauss JC; Shen T; Cui J; Ginsburg
Blood; 1996 Jun; 87(11):4718-22. PubMed ID: 8639841
[TBL] [Abstract][Full Text] [Related]
14. SERPINB2 down-regulation contributes to chemoresistance in head and neck cancer.
Huang Z; Li H; Huang Q; Chen D; Han J; Wang L; Pan C; Chen W; House MG; Nephew KP; Guo Z
Mol Carcinog; 2014 Oct; 53(10):777-86. PubMed ID: 23661500
[TBL] [Abstract][Full Text] [Related]
15. Human papilloma virus transformed CaSki cells constitutively express high levels of functional SerpinB2.
Major L; Schroder WA; Gardner J; Fish RJ; Suhrbier A
Exp Cell Res; 2011 Feb; 317(3):338-47. PubMed ID: 20974129
[TBL] [Abstract][Full Text] [Related]
16. Induction of the plasminogen activator inhibitor-2 in cells expressing the ZNF198/FGFR1 fusion kinase that is involved in atypical myeloproliferative disease.
Kasyapa CS; Kunapuli P; Hawthorn L; Cowell JK
Blood; 2006 May; 107(9):3693-9. PubMed ID: 16410451
[TBL] [Abstract][Full Text] [Related]
17. [Mechanism of tumor cell-induced extracellular matrix degradation--inhibition of cell-surface proteolytic activity might have a therapeutic effect on tumor cell invasion and metastasis].
Kobayashi H
Nihon Sanka Fujinka Gakkai Zasshi; 1996 Aug; 48(8):623-32. PubMed ID: 8808830
[TBL] [Abstract][Full Text] [Related]
18. Expression of urokinase plasminogen activator and plasminogen activator inhibitor type-1 in ovarian cancer and its clinical significance.
Zhang W; Ling D; Tan J; Zhang J; Li L
Oncol Rep; 2013 Feb; 29(2):637-45. PubMed ID: 23174953
[TBL] [Abstract][Full Text] [Related]
19. Metastatic behavior of human melanoma cell lines in nude mice correlates with urokinase-type plasminogen activator, its type-1 inhibitor, and urokinase-mediated matrix degradation.
Quax PH; van Muijen GN; Weening-Verhoeff EJ; Lund LR; Danø K; Ruiter DJ; Verheijen JH
J Cell Biol; 1991 Oct; 115(1):191-9. PubMed ID: 1918136
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of invasion of HT1080 sarcoma cells expressing recombinant plasminogen activator inhibitor 2.
Laug WE; Cao XR; Yu YB; Shimada H; Kruithof EK
Cancer Res; 1993 Dec; 53(24):6051-7. PubMed ID: 8261421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
